Trijardy XR 5 mg/1

Trijardy XR 5 mg/1 is an extended-release tablet combining empagliflozin, linagliptin, and metformin hydrochloride. It is designed to support glucose management in adults with type 2 diabetes. This medication is manufactured by Boehringer Ingelheim Pharmaceuticals, Inc. in the USA.

Trijardy XR 5 mg/1 is primarily used for managing blood sugar levels in adults with type 2 diabetes. The combination of empagliflozin, linagliptin, and metformin hydrochloride works to improve glycemic control. This medication is often prescribed as part of a comprehensive diabetes management plan, which may include diet and exercise.

Common effects of Trijardy XR 5 mg/1 may include gastrointestinal discomfort, such as nausea or diarrhea, particularly when first starting the medication. Some individuals may also experience urinary tract infections or hypoglycemia, especially when combined with other diabetes medications. It is important to monitor for any unusual symptoms and consult a healthcare provider if concerns arise.

Trijardy XR 5 mg/1 should be handled with care, especially for individuals with a history of kidney problems, as empagliflozin can affect kidney function. Metformin hydrochloride may not be suitable for those with severe liver disease. Always follow the advice of a healthcare professional regarding the use of this medication, particularly if you have other medical conditions or are taking other medications.

Trijardy XR 5 mg/1 may interact with certain medications, including other diabetes drugs, diuretics, and some antibiotics. Alcohol consumption should be avoided as it can increase the risk of lactic acidosis with metformin. Always inform your healthcare provider about all medications and supplements you are taking to avoid potential interactions.